Prachi Dalal
Nurse Practitioner · San Jose, CANPI 1134813900
Payments from drug & device makers
Across 73 payments — averaging $29.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$358
- Lundbeck LLC$235
- AbbVie$183
- Harmony Biosciences LLC$146
- AstraZeneca$146
- SK Life Science, Inc.$123
- plus $942 from 22 others
What the payments were for
- Food & beverage$2,08898%
- Education$452%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 11 | $358 |
| Lundbeck LLC | 7 | $235 |
| AbbVie | 7 | $183 |
| Harmony Biosciences LLC | 4 | $146 |
| AstraZeneca | 5 | $146 |
| SK Life Science, Inc. | 5 | $123 |
| Catalyst Pharmaceuticals, Inc. | 3 | $122 |
| Eisai Inc. | 4 | $87 |
| Lilly USA, LLC | 3 | $79 |
| Biogen | 2 | $58 |
| Pfizer | 3 | $57 |
| Livanova USA, Inc. | 2 | $54 |
| Argenx US, Inc. | 2 | $51 |
| Octapharma USA, Inc. | 1 | $49 |
| Jazz Pharmaceuticals Inc. | 1 | $39 |
| Teva Pharmaceuticals USA, Inc. | 1 | $38 |
| Merz Pharmaceuticals, LLC | 1 | $36 |
| Acadia Pharmaceuticals Inc | 1 | $33 |
| Neurelis, Inc. | 1 | $32 |
| Tanabe Pharma America, Inc. | 1 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Grifols USA, LLC | 1 | $25 |
| Genentech USA, Inc. | 1 | $25 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| CSL Behring | 1 | $20 |
| ANI Pharmaceuticals, Inc. | 1 | $19 |
| Acorda Therapeutics, Inc | 1 | $16 |
How this compares
$2,134 in reported general payments places this provider in the 85th percentile of 6,779 nurse practitioner providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 19 | $26,221 |
| Lacosamide | 57 | $23,144 |
| Gabapentin | 602 | $16,813 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 310 | $14,014 |
| Levetiracetam | 258 | $13,231 |
| Entacapone | 55 | $11,787 |
| Memantine Hcl | 308 | $7,950 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 105 | $6,794 |
| Duloxetine Hcl | 195 | $6,709 |
| Rasagiline Mesylate | 16 | $6,651 |
| Donepezil Hcl | 310 | $4,510 |
| Oxcarbazepine | 33 | $4,254 |
| Mirtazapine | 124 | $3,905 |
| Pregabalin | 81 | $3,560 |
| AmantadineAmantadine Hcl | 40 | $3,498 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $57 | $26,22119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,779 nurse practitioner providers in California.
Other nurse practitioner in San Jose
- Rhonda HewittStanford$917K
- Linda TrinhIrvine$899K
- Denise SinagaNorthridge$728K
- Debbie TaySanta Monica$642K
- Joe GorelickCampbell$638K
- Lynsey LakinArcadia$540K
- Kelly ChoiRancho Cucamonga$483K
- Hamta ZareStanford$428K
- Shawna ChrismanRoseville$425K
- Angelina CollinsSan Diego$356K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.